Inflammatory Regulation Effect of NAC on COVID-19 Treatment (INFECT-19)

Dr. Tariq Alhawassi

Status and phase: Unknown; Phase 3

Conditions: COVID-19

Treatments: Drug: Placebo; Drug: N-Acetyl cysteine

Study type: Interventional

Funder types: Other

Identifiers

NCT04455243

E-20-4934

Details and patient eligibility

About

Study times to evaluate the efficacy of N-Acetylcysteine therapy in the management of adult admitted patients with COVID-19.

Enrollment: 1,180 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult above 18 years of age
• Admitted to the hospital With confirmed COVID-19 by RT-PCR test
• On oxygen supplement

Exclusion criteria

• Active use of NAC
• Known NAC allergy
• In the opinion of the treating team, progression of death is imminent and inevitable within the next 24 hour, irrespective of provision treatment
• All patients enrolled in any other investigational drug studies in COVID-19.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

1,180 participants in 2 patient groups, including a placebo group

Intervention group

Experimental group

Treatment:

Drug: N-Acetyl cysteine

Control group

Placebo Comparator group

Treatment:

Drug: Placebo